Data from CbioPortal show that mutations in HER2 and HER3 are infrequent (4% and 3% respectively (Fig 3A) and mutually exclusive (Fig 3A); amplification of HER2 was not identified, while 1 patient (diagnosed with moderately differentiated cholangiocarcinoma) had HER3 amplified (Fig 3A and 3B)). This evidence concerns the gene ERBB3 and cholangiocarcinoma.